Navigation Links
Novel Anti-Neutrophilic Effect produced by Salmeterol in mild asthma patients

A recent three-way crossover study over six weeks by clinicians at the National Heart and Lung Institute, Royal Brompton Hospital, London has shown that Salmeterol produced a novel anti-neutrophilic effect among patients with mild asthma. The study was prompted by the long standing argument about the effects of long-acting beta2-adrenergic receptor agonists, such as salmeterol, on inflammation. The clinicians enrolled 20 patients, between the ages// of 18 and 55, with mild stable asthma who were randomized to receive salmeterol (50 micrograms b.d), fluticasone propionate (250 micrograms b.d), or placebo. They investigated the effect of salmeterol on the numbers of inflammatory cells in biopsy samples of distinct immuno-phenotype and those expressing the genes for interleukin-4 and -5, regulatory cytokines which are particularly relevant to asthma.

The numbers of neutrophils in bronchial biopsy samples and the concentrations of myeloperoxidase and soluble E-selectin in serum, each of which reflect neutrophil involvement, was found to be significantly reduced in subjects who were given salmeterol compared to those who were given the placebo. Salmeterol, compared with fluticasone propionate, reduced neutrophil number and human neutrophil lipocalin level in bronchial lavage fluid, and intercellular adhesion molecule-1 level in bronchoalveolar lavage fluid. It was also observed that the numbers of (CD3+) T-lymphocytes, (CD4+) T-helper cells, (CD45RO+) activated T-helper cells and eosinophils in the biopsy samples were significantly reduced with fluticasone propionate, compared with placebo. Fluticasone propionate also reduced the percentage of eosinophils and soluble intercellular adhesion molecule-1 in serum.

The clinicians also found that after the use of salmeterol, as compared with both fluticasone propionate and placebo, the airways hyper-responsiveness and the percentage of symptom-free days and nights improved significantly.


'"/>




Page: 1

Related medicine news :

1. Novel "CYCLOSPORINE CAPSULE FORMULATION" to be launched
2. Novel biopsy technique for prostate cancer
3. Novel computer model for breast cancer
4. Novel research on liver cancer
5. Novel way to fight cancer
6. Novel test for bowel cancer
7. Novel Therapy for Chronic Problem
8. Blood Sugar Kept In Control By Novel Protein
9. Novel antibiotic dressing developed for improved wound healing
10. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
11. Novel drug holds promise for treatment of Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/28/2016)... ... 2016 , ... May 26, 2016- In search of the K. Warriors, Shaolin ... of “K Warriors” on June 4, 2016 at Ashbury Hotel and Suites 600 West ... and hosted by Shaolin Institute and sanctioned by KSF (Kungfu Sanda Federation), This is ...
(Date:5/27/2016)... ... 27, 2016 , ... Southland Log Homes , designer and manufacturer of ... kits, which can be found on its website at SouthlandLogHomes.com. , The designs of ... they highlight the craftsmanship of timber post and beam construction. The result is ...
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... With over ... to walk, the demand for a sustainable product to aid in the rehabilitation process ... aid in the recovery of individuals with hemiplegia due to stroke. , Ekso Bionics ...
(Date:5/27/2016)... , ... May 27, 2016 , ... Beleza Medspa ... body fat composition regulations. This is the first time that Coolsculpting is being ... at least every six months to ensure they meet the prescribed body-fat standard, measured ...
(Date:5/27/2016)... ... May 27, 2016 , ... With a team ... and food industries. Aside from its GMP accreditation, Validation Center is also a ... certified products, services and staff. , Validation Center is ISO17025 accredited and only ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... , May 27, 2016 ... innovative biopharmaceutical company focused on late-stage drug development, ... Dexcel Pharma of pivotal batches required for ... Drug Administration (FDA). This follows Kitov,s announcement ... III trial successfully met its primary efficacy endpoint. ...
(Date:5/26/2016)... 2016 TARE (Transarterial Radio-embolization) ... Savings and Overall Decreased Use of Hospital ... international specialist healthcare company, has today announced the ... Meeting of ISPOR (International Society for Pharmacoeconomics and ... (HCC) using yttrium-90 glass microspheres is associated with ...
(Date:5/25/2016)... GERMANTOWN, Maryland , May 25, 2016 ... bedient dringenden Bedarf zur ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt ... und Entwicklungsvereinbarung mit Therawis Diagnostics GmbH zur Entwicklung ... zu sein. Ein erstes Projekt wird die Entwicklung ...
Breaking Medicine Technology: